Percutaneous left atrial appendage closure for stroke prevention in patients with atrial fibrillation: an assessment of net clinical benefit
- 24 September 2012
- journal article
- research article
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 33 (21), 2700-2708
- https://doi.org/10.1093/eurheartj/ehs292
Abstract
Aims The PROTECT-AF (WATCHMAN Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) trial found left atrial appendage (LAA) closure an alternative to anticoagulation in selected patients with non-valvular atrial fibrillation (AF). We aim to estimate the net clinical benefit (NCB) of percutaneous LAA closure. Methods and results Post hoc analysis of outcomes among 707 adults with AF in the PROTECT-AF trial and 566 in the Continued Access (CAP) registry undergoing LAA closure with the Watchman device compared with sustained anticoagulation. Outcomes were ischaemic stroke, intracranial haemorrhage, major bleeding, pericardial effusion, and death, weighted to reflect the relative impact in terms of death and disability. Net clinical benefit was calculated as the sum of annualized rates of these outcomes after intervention minus rates on warfarin. The NCB of LAA closure during 1623 person-years follow-up in the trial was 1.73%/year (95% CI: −0.54 to 4.39%/year) and during 741 patient-years in the registry was 4.97%/year (95% CI: 3.07–7.15%/year). Among patients with a history of ischaemic stroke, the NCB was greater in the registry (8.68%/year, CI: 2.82–14.92%/year) than the trial (4.30%/year, CI −2.07 to 11.25%/year). In the registry, the NCB of LAA closure increased from 2.22%/year (CI: 0.27–6.01%/year) in patients with CHADS2 scores = 1 to 6.12%/year (CI: 3.19–8.92%/year) in those with scores ≥2. Conclusion Combining rates of thrombo-embolism, intracranial haemorrhage, major adverse events, and death allows objective comparison of the benefit and risk of device therapy vs. anticoagulation in patients with AF. The NCB of LAA closure is greatest for patients at a higher risk of stroke.Keywords
This publication has 19 references indexed in Scilit:
- Left atrial appendage closure: a percutaneous transcatheter approach for stroke prevention in atrial fibrillationEuropean Heart Journal, 2011
- Apixaban versus Warfarin in Patients with Atrial FibrillationNew England Journal of Medicine, 2011
- A New Risk Scheme to Predict Warfarin-Associated HemorrhageJournal of the American College of Cardiology, 2011
- Left atrial appendage closure with amplatzer cardiac plug in atrial fibrillation: Initial european experienceCatheterization and Cardiovascular Interventions, 2010
- Initial Worldwide Experience With the WATCHMAN Left Atrial Appendage System for Stroke Prevention in Atrial FibrillationJournal of the American College of Cardiology, 2007
- ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: full text: A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation) Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm SocietyEP Europace, 2006
- The PROTECT AF (WATCHMAN Left Atrial Appendage System for Embolic PROTECTion in Patients with Atrial Fibrillation) TrialAmerican Heart Journal, 2006
- Percutaneous Left Atrial Appendage Transcatheter Occlusion (PLAATO System) to Prevent Stroke in High-Risk Patients With Non-Rheumatic Atrial FibrillationJournal of the American College of Cardiology, 2005
- Consecutive 1127 Therapeutic Echocardiographically Guided Pericardiocenteses: Clinical Profile, Practice Patterns, and Outcomes Spanning 21 YearsMayo Clinic Proceedings, 2002
- Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillationThe Annals of Thoracic Surgery, 1996